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ABSTRACT 
Reduced bone density and secondary osteoporosis, resulting in increased risk of fracture, is a 
significant complicating factor in the inflammatory arthritides.  While the exact etiology of 
systemic bone loss is not fully elucidated, recent insights into the tumor necrosis factor super 
family (TNFSF) revealed a potential role for death receptor 3 (DR3/TNFRSF25) and one of its 
ligands, TNF-like protein 1A (TL1A/TNFSF15).  The mechanisms by which DR3/TL1A 
signalling modulates bone loss are unclear.  We investigated the effect of DR3/TL1A signalling 
upon osteoclast-dependent chemokine and MMP production to unravel novel mechanisms 
whereby this pathway regulates OC formation and OC-dependent bone resorption.  Collagen 
induced arthritis (CIA) was established in DR3wt and DR3ko mice, joints were sectioned and 
analysed histologically for bone damage while systemic trabecular bone loss distal to the 
affected joints was compared by micro-CT.  Ablation of DR3 protected DBA/1 mice against the 
development and progression of CIA. In DR3ko, joints of the ankle and mid-foot were almost 
free of bone erosions and long bones of mice with CIA were protected against systemic 
trabecular bone loss.  In vitro, expression of DR3 was confirmed on primary human CD14+ 
osteoclast precursors by flow cytometry.  These cells were treated with TL1A in osteoclast 
differentiation medium and TRAP+ osteoclasts, bone resorption, levels of osteoclast-associated 
chemokines (CCL3, CCL2 and CXCL8) and MMP-9 measured.  TL1A intensified human 
osteoclast differentiation and bone resorption and increased osteoclast-associated production of 
CCL3 and MMP-9.  Our data reveals the DR3 pathway as an attractive therapeutic target to 
combat adverse bone pathology associated with inflammatory arthritis.  We demonstrate that 
DR3 is critical in the pathogenesis of murine CIA and associated secondary osteoporosis.  
Furthermore, we identify a novel mechanism by which the DR3/TL1A pathway directly 
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enhances human OC formation and resorptive activity, controlling expression and activation of 
CCL3 and MMP-9. 
Keywords: TNFRSF25, TNFSF15, Osteoclast, Collagen-induced Arthritis, Osteoporosis, CCL3, 
MMP-9 
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1. INTRODUCTION 
Increased prevalence of osteoporosis and decreased systemic bone mineral density at areas distal 
from affected joints are complicating factors for patients diagnosed with several forms of 
inflammatory arthritis (e.g. rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic 
arthritis (PsA)) as it can lead to significant increased risk of fracture[1–4].  The systemic 
inflammatory nature of these diseases is a substantial contributory factor to bone loss[5]. 
Evidence from clinical studies using biologics and non-steroidal anti-inflammatory drugs 
(NSAIDs) advocate the key role of cytokines (e.g. TNF, IL-1ȕ, IL-6) and PGE2 in orchestrating 
inflammation-associated bone damage[6–9].  However, inhibition or neutralization of these 
specific factors in patients does not fully ameliorate the pathology associated with inflammatory 
arthritis, as determined by the American College of Rheumatology improvement criteria 
(ACR20)[10,11].  This suggests that unresolved progressive bone disease observed during 
inflammatory arthritis may well be attributed to additional factors. Members of the tumour 
necrosis factor superfamily (TNFSF) such as LIGHT (TNFSF14), B lymphocyte stimulator 
(BLyS; TNFSF13B), a proliferation-inducing ligand (APRIL; TNFSF13A) and TNF-like protein 
1A (TL1A; TNFSF15) are elevated in the serum and / or synovial fluid of RA patients, 
potentially contributing to the bone pathology associated with the musculoskeletal disease[12–
14].  LIGHT, BLyS and APRIL are capable of signalling through numerous transmembrane TNF 
receptor superfamily (TNFRSF) members to induce their effect.  In contrast, TL1A has only 
been confirmed to bind to one transmembrane receptor, death receptor 3 (DR3; TNFRSF25)[15].  
This study focused on the role of DR3 in mediating pathological bone loss.   
Death receptor 3 (DR3; TNFRSF25, TRAMP, LARD, Apo3 and Wsl1) is involved in the 
pathogenesis of multiple inflammatory conditions such as inflammatory bowel disease, 
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atherosclerosis, allergic lung inflammation and RA[14,16–20].  To date DR3 has two confirmed 
ligands, the aforementioned TL1A, and progranulin (PGRN) / Atsttrin; which has been 
demonstrated to inhibit TL1A activity[21].  While little is currently known about the role of 
PGRN in DR3 modulation of bone more is known about DR3 / TL1A signaling.  The potentially 
important role for the DR3/TL1A pathway in regulating osteoclast (OC) formation and 
resorptive activity has been evidenced in murine and human studies. Cartilage damage and focal 
bone erosion were reduced or inhibited by DR3 or TL1A gene ablation in the murine models, 
antigen-induced arthritis (AIA) and collagen-induced arthritis[22–24].  Furthermore, addition of 
TL1A to human peripheral blood mononuclear cell (PBMC) cultures in the presence of 
macrophage colony stimulating factor (MCSF) and receptor activator of nuclear factor kappa B 
ligand (RANKL) enhanced OC formation[22]. These data imply an important role of DR3/TL1A 
in modulating osteoclastogenesis and bone resorption, however, the underlying mechanisms are 
unclear.  
Signalling through the DRγ/TL1A pathway following IFNȖ priming on human PBMC-derived 
CD14+ macrophages and the monocytic THP-1 cell line induced expression of the chemokines 
CCL2 and CXCL8[25,26]. The function of these chemokines is not limited to cell trafficking as 
they also act as key mediators in the mobilisation of OC precursors and OC differentiation.  
Indeed, elevated expression of the chemokines CCL2, CCL3 and CXCL8 have been described in 
the serum and synovial fluid of RA patients while in vitro they have been demonstrated to 
enhance RANKL-induced OC formation[27–32].  These chemokines however, have not 
previously been linked with DR3/TL1A dependent osteoclast-associated bone damage. While 
chemokines play a role in OC formation they are not directly involved in osteoclastic bone 
resorption.  Dissolution of calcium by acidification of the resorption lacunae and proteolysis of 
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the organic matrix by matrix metalloproteinases (MMPs), the cysteine proteinase cathepsin K 
and the metalloenzyme tartrate resistant acid phosphatase (TRAP) results in bone 
degradation[33–35]. MMP-9 specifically, is implicated in osteoclast bone resorption[35,36]. 
Increased expression of MMP-9 has also been described in RA patient serum and is correlated 
with the collagen degradation marker hydroxyproline (OHPro), furthermore MMP-9 expression 
was reduced in DR3ko joints undergoing AIA[24].  These initial findings suggest that CCL2, 
CXCL8 and MMP-9 are important downstream effector molecules by which DR3/TL1A 
signalling drives pathologic systemic bone loss observed in the inflammatory arthritides. 
In the present study we demonstrate a critical role for DR3 in the pathogenesis of joint erosions 
in murine CIA and additionally reveal that DR3 drives secondary osteoporosis at sites distal from 
the affected small joints, using DBA/1 mice lacking the DR3 gene (DR3ko).  In vitro, we identify 
for the first time that DR3 is expressed on human CD14+ OC precursors and differentiating OC.  
We report that TL1A directly increases OC differentiation and resorptive activity in a 
concentration-dependent fashion and that this is not through CCL2, but via elevated expression 
of the osteoclastogenic chemokine CCL3 and enhanced activation of the gelatinase MMP-9. 
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2. MATERIALS AND METHODS 
2.1 Animals and CIA 
All animal experiments were undertaken in 6-8 week-old male DBA/1 DR3wt and DR3ko 
mice[37].  Procedures were performed in accordance with Home Office-approved licenses PPL 
30/2361 and 30/2928 and complied with ARRIVE guidelines. Induction of CIA, assessment of 
severity (paw scores) and inflammatory parameters (arthritis index) were carried out as 
previously described[24,38,39] (see supplementary methods). 
2.2 Histological Assessment of CIA joints 
Architectural changes and inflammatory parameters caused by CIA were assessed histologically 
in the left hind leg (DR3wt baseline n = 5, DR3wt CIA n = 15  and DR3ko baseline n = 5, DR3ko 
CIA n = 8) as previously described to assign an arthritis index score[38,39] (see supplementary 
methods). 
2.3 Micro-Computed Tomography (µCT) Analysis 
In separate experiments, the right hind limbs (DR3wt baseline n = 5, DR3wt CIA n = 14 and 
DR3ko baseline n = 5, DR3ko CIA n = 8) were scanned using a GE Explore Locus microcomputed 
tomography (µCT) system at 20µm voxel resolution obtained from 720 views. Beam angle of 
increment was 0.5; beam strength 80 peak-kV and 450uA. Each blind run included DR3wt and 
DR3ko baseline and CIA bones, and a calibration phantom to standardize grayscale values and 
maintain consistency.  Femoral bone analyses were performed in trabecular bone (1% of total 
length proximal to the growth plate, extending 2mm toward the diaphysis, excluding outer 
cortical bone). Trabecular bone mineral content (BMC), bone volume/total volume (BV/TV), 
trabecular thickness (Tb.Th), spacing (Tb.Sp), and number (Tb.N) values were computed by 
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MicroView software (GE).   Cortical measurements were performed in a 2x2x2mm cube midway 
down the bone.  
2.4 Human Osteoclastogenesis Assays and Analysis of Resorption Pits 
Ethical approval was obtained from the Medical/Dental School Research Ethics Committee 
(09/21, Cardiff University, UK).  Human peripheral blood mononuclear cells were isolated from 
healthy female volunteers (n = 7) by density gradient centrifugation using Histopaque-1077 
(Sigma), and CD14+ monocytes isolated by magnetic cell sorting following manufacturer’s 
instructions (Miltenyi Biotec, UK). Cells (6.4x104; >95% CD14+ purity) were added to ivory 
discs in RPMI supplemented with 10% FCS, 20mM L-glutamine and 50μg/ml 
Penicillin/Streptomycin (RPMI-10).  After 2hrs at 37°C 5% CO2, discs were transferred to 48-
well plates and RPMI-10 with MCSF (5ng/ml) added.  Media was replenished after 3 days and 
cells stained for DR3 after 7 days (classified as day 0 for OC assays).  Media was replenished 
every 3-4 days using RPMI-10 supplemented with MCSF (5ng/ml), RANKL (5ng/ml), anti-
polyHistidine (2.5µg/ml) ± TL1A (10 or 100ng/ml), all from R&D systems. Supernatants were 
stored at -80°C for further analysis.  3 discs per condition were stained for TRAP on days 7, 10 
and 14.  Images of five random areas of the discs were taken at x10 magnification using a BX41 
microscope and Camedia C-γ0γ0 camera (Olympus, UK) and cropped to represent 1000μm2 
(Corel Paint Shop Pro, Corel, UK).  The number of TRAP-positive multinucleated cells and 
TRAP-negative/positive mononucleated cells were counted and results reported per disc.  For 
resorption pits, discs minus cells and hematoxylin, were stained with toluidine, photographed 
and analysed as above (see supplementary methods).   
2.5 Flow Cytometry 
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Isolated human peripheral blood CD14+ monocytes (n = 7) and cells isolated from OC cultures 
(n = 1 per time-point) were stained with anti-DR3-PE (clone JD3) and anti-CD14-FITC (clone 
61D3) (eBioscience).  Data were acquired on an Accuri C6 flow cytometer and analysed with 
CFlow software (BD Biosciences). 
2.6 Murine CIA Serum and Human Osteoclastogenesis Cell Culture Supernatant Analysis  
DR3wt and DR3ko CIA serum levels of IFNȖ, TNFα, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, 
IL-17A, IL-17F, IL-21 and IL-22 were analysed using LEGENDplex Mouse Th Cytokine Panel 
(BioLegend, San Diego, CA) according to the manufacturer’s instructions.  Levels of CCL2, 
CCL3, CXCL8 and total MMP-9 in human osteoclastogenesis assay supernatants were measured 
using DuoSet kits (R&D Systems).  TNFα was measured in human osteoclastogenesis assay 
supernatants using an OptEIA kit (BD Biosciences). 
2.7 Active MMP-9 Zymogram 
MMP-9 activity was determined by gelatine zymography following manufacturer’s instructions 
(Bio-rad) (see supplementary methods).  In Vivo FX Pro and Molecular Imaging Software 
(Carestream) were used to scan gels and visualize bands. 
2.8 Statistical Analysis 
Data are expressed as mean±SEM, and statistical analysis (Mann-Whitney U-Tests for non-
parametric, unpaired t-Tests for parametric data, 1-way or 2-way analysis of variance (ANOVA)) 
performed using GraphPad Prism software (GraphPad, San Diego, USA). p-values of <0.05 were 
considered significant and p-values of <0.01 highly significant. 
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3. RESULTS 
3.1 DR3ko Mice are Protected against Focal Bone Erosion in Response to Collagen-Induced 
Arthritis  
Ablation of TL1A in a model of CIA has previously been demonstrated to partially block 
inflammation and focal bone erosion associated with the disease pathology[23].   The use of 
DR3ko mice to investigate the pathogenesis of inflammation and focal bone erosion in CIA 
however, has never been carried out.  This is increasingly relevant as novel non-TNFSF ligands 
for DR3 that impact on TL1A signalling, such as PGRN, have recently emerged [21]. Significant 
increases in arthritis severity, as determined by joint swelling and number of affected joints, were 
observed in the DR3wt CIA cohort compared to DR3wt baseline controls (p<0.05).  In contrast, 
arthritis severity in the DR3ko CIA cohort did not differ significantly from the DR3ko controls 
(Fig 1a).  Histological analysis (arthritis index) of hind limbs at experimental endpoint further 
confirmed the importance of DR3 in CIA pathology.  While the DR3wt CIA mice exhibited a 
significantly higher arthritis index compared to the DR3wt baseline (p<0.001), there was no 
significant difference observed in arthritis index between the DR3ko CIA mice compared to 
baseline mice.  More importantly, a significantly lower arthritis index in DR3ko CIA compared to 
DR3wt CIA mice (p<0.01) was observed (Fig 1b, c). Analysis of cytokine expression in the 
serum of DR3wt and DR3ko CIA mice identified no significant difference in levels of IFNȖ, 
TNFα or IL-6 (supplementary data Fig 1).  All other cytokines investigated were below the limit 
of detection. 
3.2 Absence of DR3 Protects Against Systemic Trabecular Bone Loss in the Distal Femur 
during Collagen-Induced Arthritis 
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Generalized bone loss is a complicating factor in the pathogenesis of inflammatory arthritis 
leading to increased risk of fracture[1,4].  We investigated whether absence of DR3 signalling 
could protect against systemic trabecular bone loss, distal from affected small joints, in the 
murine CIA model.  As a measure of bone health, µCT was used to analyse the distal femur.  
Analysis of cortical bone parameters (table 1) did not identify any significant differences 
between baseline and CIA cohorts. In contrast, the metaphyseal trabecular region displayed a 
significant decrease in bone volume fraction (BV/TV) in both CIA DR3wt (p<0.0001) and CIA 
DR3ko (p<0.01) mice compared to their baseline controls (Fig 2c). However, the DR3ko CIA 
mice had significantly greater trabecular BV/TV than DR3wt CIA mice (DR3wt = 6.0±1.1%, 
DR3ko = 10.2±1.1%; p<0.05).  Similarly, CIA significantly decreased trabecular number (Tb.N) 
in both DR3wt (p<0.0001) and DR3ko (p<0.05) mice, but the decrease was greater in DR3wt CIA 
compared to DR3wt controls (table 1).  Trabecular thickness (Tb.Th, p<0.0001) was only 
significantly decreased by CIA in DR3wt but not DR3ko mice. DR3ko CIA mice showed 
significantly increased Tb.N (p<0.05) and decreased Tb.Sp (p<0.05) compared to DR3wt CIA 
animals. 
3.3 Expression of DR3 is Induced by MCSF and the Presence of a Bone Substrate on 
Human CD14+ Osteoclast Precursors 
Ablation of DR3 signalling protected the ankle against CIA-induced focal bone erosion and the 
distal femur from systemic bone loss, implying that the DR3/TL1A pathway in mice promotes 
OC-dependent bone pathology during inflammatory arthritis.  Addition of TL1A to 
osteoclastogenic human PBMC cultures has also been demonstrated to enhance OC formation 
[22].  However, it is unclear from these results whether the action of TL1A is through an indirect 
mechanism, via CD4+ T cells, or a direct effect on the OC precursors.   To determine if TL1A 
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can directly signal to human OC precursors, expression of DR3 was examined on isolated human 
peripheral blood CD14+ monocytes by flow cytometry. Samples were derived from females as 
osteoporosis and RA are more prevalent in women[40,41].  While DR3 expression was not 
detected on the surface of freshly isolated CD14+ monocytes, it was up-regulated following 
culture for 7 days in MCSF on ivory discs indicating that TL1A could directly signal to the 
expanded population of osteoclast precursors (Fig 3a).  Expression of DR3 was maintained in 
osteoclast-containing cultures throughout the period of differentiation by RANKL and MCSF 
(Fig 3b).  DR3 expression was not induced on cells cultured on a glass substrate (supplementary 
data Fig 2) 
3.4 TL1A Directly Increases Osteoclast Formation from Human CD14+ Osteoclast 
Precursors and Upregulates Osteoclast Resorption in a Concentration-dependent Manner 
Having demonstrated that human CD14+ OC precursors express DR3 we next sought to 
determine the direct effect of TL1A signalling on CD14+ precursor OC formation and OC 
resorptive activity.  To assess the impact of this, osteoclastogenesis assays using purified CD14+ 
monocytes on ivory discs were carried out and the number of total cells (TRAP- and TRAP+) and 
TRAP+ multinucleated cells per mm2 counted.  At day 7, total cell numbers in control cultures 
were 518±33, comparable to those with 10 ng/ml (582±31) and 100 ng/ml TL1A (569±26) and 
did not change significantly throughout the time-course (Fig 4a).  In contrast, addition of TL1A 
had a significant concentration-dependent effect on OC formation as did time, however no 
interaction between the two was observed (2-way ANOVA: Time p<0.05, TL1A p<0.001).  At 
days 10 and 14, OC numbers were marginally increased in the 10 ng/ml (10±1 and 11±1, 
respectively) and significantly in the 100 ng/ml TL1A cultures (9±1 and 12±2 respectively; 
p<0.05) when compared to cultures without TL1A (8±1 and 7±1, respectively).  This translated 
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into a significant increase in OC numbers in both the 10 ng/ml (p<0.01) and 100 ng/ml TL1A 
cultures across the time-course (p<0.001; Fig 4b, c).  In the absence of RANKL, TL1A had no 
effect on total cell numbers and was unable to induce osteoclast formation (supplementary data 
Fig 3). 
To determine the functional consequences of increased OC differentiation, the % area resorbed 
by OC of the ivory discs was measured.  At day 10 in cultures without TL1A, resorption was 
calculated as 0.9±0.3%, which increased in the 10 ng/ml (1.8±0.4%) and 100 ng/ml (1.6±0.4%) 
TL1A cultures.  At day 14, significantly increased resorption was observed in 10 ng/ml 
(2.8±0.4%; p<0.01) and 100 ng/ml TL1A cultures (5.2±1.6%; p<0.001) compared to those 
without TL1A (1.3±0.3%).  This translated into significantly elevated resorption in the 10 ng/ml 
TL1A (p<0.001) and 100 ng/ml TL1A (p<0.01) cultures across the time-course (Fig 4d, e). 
3.5 TL1A Signalling Enhances RANKL-Induced Expression of the Osteoclastogenic 
Chemokine CCL3 
The mobilisation of OC precursors to sites of resorption and subsequent formation of OC is 
controlled by chemokines, including CCL2, CXCL8 and CCL3[31,42].   Addition of TL1A had 
no effect on expression of CCL2 (Fig 5a (i)) and CXCL8 (Fig 5a (ii)) in osteoclast-containing 
cultures.  However, TL1A had a profound effect on levels of CCL3 (2-way ANOVA: Time 
p<0.0001, TL1A p<0.05).  Across the 14-day time-course a significant overall increase in CCL3 
secretion was detected in 100 ng/ml TL1A treated cells compared to untreated cultures (p<0.01; 
Fig 5a (iii)).  Expression of CCL3 had a positive and significant correlation with OC numbers at 
day 7 (r = 0.53, p<0.01; Fig 5b (i)), day 10 (r = 0.51, p<0.01; Fig 5b (ii)) and day 14 (r = 0.46, 
p<0.05; Fig 5b (iii)).  TL1A had no effect on CCL2, CXCL8 and CCL3 expression in cultures 
without RANKL (supplementary data Fig 4). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
14 
 
3.6 TL1A Signalling Increases RANKL-Induced MMP-9 Expression and Brings Forward 
Detection of Active MMP-9 in Osteoclast Cultures 
MMP-9, a gelatinase expressed by OC and their precursors, cleaves collagen present in the 
organic matrix during osteoclastogenic bone degradation[35].  In the present study TL1A was 
observed to increase total MMP-9 expression (2-way ANOVA: Time p<0.0001, TL1A p<0.001) 
with a significant increase detected across the 14-day time-course in osteoclast cultures 
containing 100 ng/ml TL1A compared to OC cultures containing 10 ng/ml TL1A (p<0.05) and 
cultures without TL1A (p<0.001; Fig 5c (i)).  At day 14, total MMP-9 expression correlated 
positively with % area resorbed (r = 0.49, p<0.01; Fig 5c (ii)).  A gelatine zymogram was used to 
detect active MMP-9.  The cleaved active form of MMP-9 was not detected at the start of the OC 
cultures (day 0). From day 3 onwards active MMP-9 was detected in OC cultures containing 100 
ng/ml TL1A compared to day 7 in cultures without TL1A (Fig 5d), suggesting that increasing 
levels of TL1A promotes activation of MMP-9. 
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4. DISCUSSION 
Prior to this study DR3 has been shown to drive early cartilage destruction and bone pathology 
associated with the murine AIA model of inflammatory arthritis[22,24].  However, this model 
does not recapitulate the endogenous breach of tolerance that is typical of RA pathogenesis and 
as such is limited in its applicability to the disease[43].  To address these shortcomings we 
utilized the murine model of CIA which shares many immunological and pathological 
similarities with RA: generation of autoantibodies towards self, breach of tolerance, symmetrical 
joint involvement, peripheral joints affected  and systemic development of synovial hyperplasia, 
pannus formation and subsequent bone resorption[43–45]. In addition to DR3, TL1A, one of 
DRγ’s two confirmed ligands, has also been demonstrated to contribute to the development and 
progression of focal bone erosions in murine models of inflammatory arthritis[23], while 
increased levels are observed in the serum and synovial fluid of patients with inflammatory 
arthritis[14].  These data highlight a significant role for DR3 in pathological bone loss however, 
the mechanism through which DR3 signalling acts upon bone-altering cells remains poorly 
defined.  In the current study we sought to identify the role of DR3 in the CIA model of 
inflammatory arthritis-induced bone loss and reveal the mechanism by which DR3/TL1A 
signalling affected human OC formation and resorptive activity. 
We demonstrate for the first time that ablation of DR3 protects against focal bone erosions in a 
CIA murine model of inflammatory arthritis; the gold standard in vivo model for RA studies.  
We further reveal that absence of DR3 protected against systemic trabecular bone loss, distal 
from the affected small joints.  In an in vitro human system, we show DR3 expression on CD14+ 
OC precursors and differentiating OC and that TL1A can directly affect OC differentiation by 
increasing expression of the osteoclastogenic chemokine CCL3. TL1A also increased OC 
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resorptive activity, associated with enhanced expression and activation of MMP-9. All these 
effects are TNFα-independent as no TNFα was detected in cultures (Supplementary data Fig 5). 
The pathogenesis of inflammatory arthritis leads to focal bone erosions of small joints and 
systemic bone loss, resulting in an increased risk of fracture[4,46].  Prior to this study the role of 
DR3 in this pathology had not been fully described, as the DR3-deletion mutant was not 
available on the murine DBA background.  We describe for the first time murine CIA in the male 
DR3ko mouse; as the penetrance of this model is very reproducible and less inclined to variability 
compared to female mice[47]. Ablation of DR3 resulted in reduced arthritis severity, as 
determined by reduced swelling and number of affected joints when compared to the DR3wt.  
Furthermore DR3ko mice were significantly protected against focal bone erosions. These results 
reveal a critical role for DR3 in the pathogenesis of systemic joint damage in inflammatory 
arthritis and supports the findings observed in DR3ko mice on a C57BL/6 background in the AIA 
inflammatory arthritis model[24].This protection against focal bone erosion and inflammation is 
not due to any baseline cellular abnormality in the myeloid cells from DR3ko mice.  Under 
canonical conditions, DR3ko osteoclastogenesis from bone marrow-derived macrophages has 
been demonstrated to be comparable to that of the DR3wt, while the addition of TL1A only 
boosted osteoclastogenesis in DR3wt cultures[22].  Furthermore, studies have shown no 
significant difference in naïve T cell populations in the periphery or lymphoid tissue [48].  
Studies investigating both the TL1Ako in CIA and DR3ko mouse in other inflammatory models 
revealed no significant differences in the capacity to differentiate Treg (FoxP3+), Th1 and Th17 
cells in relation to wildtype animals [23,49].  However, studies using splenic T cells from wild-
type and DR3ko mice identified that TL1A signalling through DR3 supported the maintenance of 
T cell IL-17A expression [50],the expansion of effector T cells at sites of disease [49], expansion 
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of T cells following viral infection[51] and expansion of T cells following bacterial infection[52] 
.  This suggests that the DR3 / TL1A pathway is not required for baseline maintenance of cell 
profiles and number but under inflammatory conditions maintains the signal to drive their 
expansion.  In addition to identifying a role for DR3 in regulating joint damage we revealed a 
novel role in systemic bone loss.  Analysis of both DR3wt and DR3ko CIA mice showed a 
reduction in femoral trabecular bone compared to their non-CIA controls, however, the amount 
of trabecular bone loss in DR3ko mice was significantly less than their DR3wt counterparts.  This 
suggests that CIA-induced trabecular bone loss is DR3-dependent, though further experiments 
would be required to determine the relative contribution of DR3 on myeloid, lymphoid and 
stromal cells.  This result reveals a previously unappreciated effect of DR3 signalling in distal 
systemic bone loss associated with the inflammatory arthritides[1–4]. Interestingly, no difference 
in serum cytokine expression was observed between the DR3wt and DR3ko CIA mice at 
experimental endpoint.  This suggests that the protection from both focal and systemic bone loss 
observed in the DR3ko mice is directly dependent on the ablation of DR3 signalling and is not a 
consequence of subsequent changes in levels of other pro-inflammatory cytokines.  The 
importance of these findings are increased following the discovery of a second ligand for DR3, 
PGRN / Atsttrin, which signals negatively through DR3 inhibiting the effects of TL1A[21].  
While earlier studies by Bull, Williams et al[22] and Wang et al[23] identifed that treatment of 
CIA using a TL1A antagonist, or ablation of TL1A, protected against focal bone erosion it was 
unknown whether this was due to decreased DR3 signalling or increased DR3 / PGRN 
signalling.  
While DR3/TL1A signalling has been implicated in pathological bone loss, its mechanism of 
action was not certain.  Bull, Williams et al[22] showed that addition of exogenous TL1A to 
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PBMC cultures enhanced OC formation, but it was unclear whether the effect of TL1A was 
directly on the OC precursors (CD14+ monocytes) or via an intermediary cell type (e.g. CD4+ T 
cells).  An indirect effect would be in keeping with reports that TL1A enhances CD4+ Th17 
differentiation in RA patients, maintains Th17 numbers, with IL-17 subsequently enhancing OC 
differentiation[50,53,54]. In the present study, CD14+ monocytes isolated from human pre-
menopausal females were utilized as a source of osteoclast precursors; as females are 
significantly more prone to developing osteoporosis and RA  [40,41].  Furthermore, under 
canonical conditions pre-menopausal females have been shown to exhibit similar levels of 
osteoclastogenesis to matched males thus no hormonal effects were expected [55].  DR3 was not 
found on circulating CD14+ monocytes, in agreement with previous reports[25].  However, its 
expression was induced following culture in the presence of MCSF on an ivory substrate, but not 
glass.  This suggests that signals supplied by the local environment and substrate are important in 
DR3 induction; with signalling by Ca2+ through the calcium sensing receptor (CaSR) potentially 
key in the induction of DR3 expression on osteoclast precursors [56].  However, these data 
reveal that TL1A can signal directly through DR3 on CD14+ OC precursors.   
Studies into the effect of TL1A signalling on effector T cells have demonstrated that it drives 
proliferation[49,51]. Here, addition of TL1A to CD14+ monocyte OC cultures had no effect on 
precursor expansion, indicating differential effects depending on cell type.  Irrespective, TL1A 
had a concentration-dependent effect on eventual OC numbers as measured by TRAP staining, 
implying action through induction of OC differentiation.  This is the first time in a primary 
human system that TL1A has been shown to act directly on OC precursors to enhance OC 
formation and is consistent with effects observed in murine RAW264.7 macrophage cells[21].  
In addition to increasing OC formation, in the current study TL1A was observed to have a 
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concentration-dependent effect on resorptive activity consistent with previous reports[22,57]. 
However, it was not clear from these studies whether the increase in resorptive function was a 
result of the increase in OC numbers or as a result of an increase in the resorptive capacity of the 
OC.  To investigate the underlying mechanisms which resulted in the increased OC formation 
and resorption, culture supernatants were analysed for soluble mediators. 
Osteoclast differentiation is the process by which mononuclear cells migrate and undergo fusion 
into the multinucleated OC and is controlled in part by chemokines.  The chemokines CCL2, 
CXCL8 and CCL3 have all been shown to have roles in osteoclastogenesis;  CCL2-deficient 
mice exhibit significantly reduced OC numbers while addition of exogenous CCL2, CXCL8 or 
CCL3 to OC cultures enhances RANKL-induced OC formation[29–31].  Interestingly, CCL3-
null mice and anti-CCL2 treated rats are protected against bone damage in models of CIA, 
further highlighting the importance of these chemokines in OC pathology[58,59].  In consensus 
with the studies by Kang et al[25] and Su et al[60], CCL2 production was not affected by the 
addition of TL1A.  Contradictory to these papers however, we report that TL1A had no effect on 
CXCL8 expression. This difference may be due to: use of THP-1 cells; higher concentrations of 
TL1A and; co-stimulation with IFNȖ in the Kang et al[25] and Su et al[60] studies. Instead, we 
found CCL3 expression increased in a concentration-dependent manner implying that this is a 
downstream target of DR3/TL1A signalling. CCL3 levels also correlated with OC numbers 
across the time-course, but were unaffected by the addition of TL1A alone suggesting that TL1A 
effects on CCL3 are RANKL-dependent. Perhaps more significantly with regards to human 
disease, increased concentrations of CCL3 are present in serum and synovial fluid from RA 
patients and in serum of PsA patients[27,61,62].   
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To determine the mechanism for the increased bone resorption the gelatinase MMP-9 was 
investigated.  MMP-9 has been shown to have a role in bone resorption[35,36].  Increased 
expression of MMP-9 has also been identified in RA patients[63] while in murine models of 
inflammatory arthritis a milder pathology has been observed in MMP-9 KO mice[64]. 
Furthermore, MMP-9 is induced by TL1A signalling in THP-1 cells[25], has been found to be 
reduced in DR3ko joints undergoing AIA[24] and levels of the active form are reduced in DR3ko 
osteoclast cultures (supplementary data Fig 6), implying that MMP-9 is a key downstream target 
of DR3/TL1A signalling.  In the present study, TL1A increased levels of total MMP-9, which 
correlated significantly with levels of resorption. However, for MMP-9 to be functionally active 
it must be cleaved into its active form [65].  TL1A brought forward the time-point at which 
active MMP-9 was first observed.  Whether this is due to the increased amount of total MMP-9, 
or TL1A promoting cleavage of MMP-9 to its active form, remains to be seen.   This and the fact 
that TL1A-dependent MMP-9 release from primary myeloid cells may require additional 
priming events[24], indicate that the relationship between TL1A and MMP-9 is complex and 
requires further investigation.   
In summary, we have identified for the first time in vitro, that the osteoclastogenic chemokine 
CCL3 and the gelatinase MMP-9 are induced downstream of DR3/TL1A signalling on primary 
human CD14+ OC precursors.  We show that TL1A concentration-dependently increases OC 
formation and resorptive activity by increasing expression of CCL3 and expression and 
activation of MMP-9.  Combined with our in vivo CIA data we demonstrate the importance of 
DR3 signalling in the progression of pathologic OC activity associated with inflammatory 
arthritis-induced focal bone erosion and secondary osteoporosis.  
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Figure Legends 
Fig 1: Absence of DR3 Protects Against Collagen-induced Arthritis 
CIA was induced in male DR3wt and DR3ko mice bred onto a DBA/1 background.  a) Arthritis 
severity was determined by level of paw swelling.  DR3wt CIA mice had significantly worse 
arthritis severity (p<0.05) compared to the DR3wt baseline control. No significant difference was 
observed between the DR3ko CIA and DR3ko baseline controls. b) Summary data of pathology by 
an arthritis index determined by scoring for erosion, cellular infiltrates, exudate and hyperplasia.  
Arthritis index was significantly lower in DR3ko CIA compared to DR3wt CIA mice (p<0.01); 
n=5-15 mice per group.  c) Representative micrographs of joints from DR3wt and DR3ko mice 
following CIA induction: e = erosion; p = pannus formation; sh = synovial hyperplasia; si = 
synovial infiltration; l = loss of joint space.  Scale bar=0.1mm.  Statistical analysis performed 
with unpaired students t-test. 
Fig 2: Absence of DR3 Protects Against Systemic Bone Loss Associated with Collagen-
induced Arthritis 
CIA was induced in male DR3wt and DR3ko mice.  Representative images of a. i) control and ii) 
severe arthritis ankle joints showing erosions.  Arrows indicate areas of erosion.  b)  
Representative image of distal femoral trabecular region analyzed by µCT.  c) Distal femoral 
trabecular BV/TV was determined by µCT.  Both DR3wt (p<0.0001) and DR3ko (p<0.01) CIA 
mice significantly lost trabecular bone compared to relevant baseline control. DR3wt CIA mice 
lost significantly more trabecular bone than DR3ko counterparts (p<0.05).  d) Representative 
µCT isosurface images.  Scale bar=1mm. n=5-14 mice per group.  Statistical analysis performed 
with 1-Way ANOVA and Holm-Šídák post-test. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
33 
 
Fig 3: Expression of DR3 on Human CD14+ Monocyte Osteoclast Precursors 
CD14+ monocytes were isolated from pre-menopausal females (n=7) and cultured on ivory discs 
for 7 days in media+MCSF. DR3 expression was determined by flow cytometry. a) DR3 was not 
detected on freshly isolated CD14+ monocytes but confirmed after 7 days culture in MCSF (light 
grey line=isotype, shaded peak=DR3). b) DR3 expression was maintained in cultures following 
addition of RANKL (black line=isotype, grey line=DR3).   
Fig 4: TL1A Concentration-dependently Increases Osteoclast Formation and Osteoclast 
Resorption 
CD14+ monocytes were isolated from pre-menopausal females (n=7) and cultured on ivory discs 
for 7 days in media+MCSF.  Cells were differentiated for 7, 10 or 14 days in the presence of 
MCSF (M) and RANKL (R) ± TL1A (T) at 10ng/ml or 100ng/ml.  At experiment end-points 
cells were stained for TRAP. a) TL1A had no effect on total cell number.  b) A significant 
increase in OC numbers was observed in the 10ng/ml (p<0.01) and the 100ng/ml (p<0.0001) 
TL1A cultures across the time-course.  c) Representative images of TRAP stained i) control and 
ii) 100ng/ml TL1A cultures at day 14. Scale bar=250µm.  Arrows indicate multinucleated OC.  
d) Discs were stained with toluidine blue and % area resorbed calculated.  Significantly 
increased resorption was observed in the 10ng/ml (p<0.0001) and 100ng/ml (p<0.01) TL1A 
cultures across the time-course compared to control. e) Representative day 14 confocal images of 
i) control, ii) 10ng/ml and iii) 100ng/ml TL1A culture resorption pits.  Statistical analysis 
performed with 2-Way ANOVA and Bonferroni post-test. 
Fig 5: TL1A Concentration-dependently Increases Expression of the Osteoclastogenic 
Chemokine CCL3 and Gelatinase MMP-9 
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CD14+ monocytes were isolated from pre-menopausal females (n=7). Cells were cultured on 
ivory discs for 7 days in media+MCSF and further differentiated for 7, 10 or 14 days in the 
presence of MCSF (M) and RANKL (R) ± TL1A (T) at 10ng/ml or 100ng/ml. Culture 
supernatants were collected at indicated time-points and tested for a)i) CCL2, ii) CXCL8 and iii) 
CCL3. Significantly increased CCL3 levels were detected across the time-course in 100ng/ml 
TL1A cultures compared to control (p<0.01).  No differences were observed in CCL2 and 
CXCL8 levels.  b) CCL3 levels significantly correlated with OC numbers at (i) day 7, (ii) day 10 
and (ii) day 14.  c)i) Significantly increased total MMP-9 expression was observed in the 
100ng/ml TL1A cultures across the time-course compared to control (p<0.0001) and 10ng/ml 
TL1A cultures (p<0.05).  ii) Levels of total MMP-9 significantly correlated with % area resorbed 
at day 14.  d) Levels of pro- and active-MMP-9 in cultures were determined by gelatine 
zymography (n=4).   Representative zymograms for control (MR) and 100ng/ml TL1A (MRT) 
cultures.  Pro-MMP-9 was detected in both cultures across the time-course.  Active MMP-9 was 
first detected at day 3 in the 100ng/ml TL1A OC cultures and day 7 in control cultures.  Samples 
run in duplicate. Statistical analysis performed with 2-Way ANOVA and Spearman correlation. 
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Table 1: Femoral and Cortical Bone Parameters 
 
Femoral Parameters 
Baseline CIA 
DR3wt DR3ko DR3wt DR3ko 
BV / TV 18.96±1.4 17.94±1.9 5.95±3.6a 10.21±1.9ab 
Tb. N (1/mm) 4.6±0.2 4.9±0.4 1.96±0.3a 3.20±0.2ab 
Tb. Th (µm) 41.2±2.0 36.2±1.2 29.1±1.3a 31.6±2.1 
Tb. Sp (mm) 0.18±0.01 0.17±0.02 0.73±0.14a 0.29±0.03b 
Cortical Parameters     
Tt. Ar. (mm2) 1.21±0.01 1.24±0.09 1.32±0.02 1.32±0.02 
Ct. Ar. (mm2) 0.80±0.02 0.82±0.07 0.91±0.02 0.89±0.03 
Ma. Ar. (mm2) 0.44±0.02 0.41±0.04 0.41±0.01 0.42±0.02 
BMD (mg/cc) 748±64 775±48 649±49 685±80 
BMC (mg) 0.012±0.001 0.014±0.002 0.013±0.000 0.012±0.001 
a - significant to base line, b - significant compared to DR3wt CIA 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
36 
 
Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Highlights 
CCL3 and MMP-9 are Induced Downstream of Death Receptor 3 (TNFRSF25)-Dependent 
Osteoclast Function and Systemic Bone Loss 
 Joint pathology of CIA, a murine model of rheumatoid arthritis, described for the first 
time in the DBA DR3ko  mouse  Absence of DR3 not only protects against focal bone erosion but also abrogates CIA-
induced distal systemic bone loss  DR3 expression identified for the first time on human CD14+ osteoclast precursors and 
differentiating osteoclasts   TL1A, a DR3 ligand, concentration-dependently increases RANKL-induced osteoclast 
formation and resorption in vitro  TL1A concentration-dependently increases RANKL-induced expression of the 
osteoclastogenic chemokine CCL3 and the gelatinase MMP-9 in vitro 
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